NFKB1 and Miyoshi myopathy: Furthermore, targeted shRNA-mediated run-down of NIK abrogates non-canonical NF-κB activity and generates toxicity to NIK-overexpressing MM cells [126], thus suggesting pharmacological intervention against NIK may be a future therapeutic strategy [126].